Protagonist Therapeutics Inc (PTGX)

Jul 24, 2025

What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia

Jul 24, 2025

Jul 24, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News

Jul 24, 2025

Jul 23, 2025

Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India

Jul 23, 2025

Jul 23, 2025

Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal

Jul 22, 2025

Jul 21, 2025

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

Jul 21, 2025

Jul 21, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

Jul 21, 2025

Jul 17, 2025

How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com

Jul 17, 2025

Jul 15, 2025

How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser

Jul 15, 2025

Jul 15, 2025

Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025

Jul 15, 2025

What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser

Jul 15, 2025

Jul 12, 2025

Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛

Jul 12, 2025

Jul 02, 2025

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech

Jul 02, 2025

Jul 01, 2025

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com

Jul 01, 2025

Jun 30, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener

Jun 30, 2025

Jun 30, 2025

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - Worcester Telegram

Jun 30, 2025

Jun 26, 2025

Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus

Jun 26, 2025

Jun 24, 2025

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance

Jun 24, 2025

Jun 20, 2025

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance

Jun 20, 2025

Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025

Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025

Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025

Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025

Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025